Medicinska fakulteta, Medicinska fakulteta, Univerzitetna založba Univerze v Mariboru
Doi
Abstract
Presaditev trebušne slinavke je zlati standard za zdravljenje ledvične odpovedi pri bolnikih s sladkorno
boleznijo oz. pri bolnikih s sladkorno boleznijo, kjer kljub intenzivirani inzulinski terapiji ne uspemo preprečiti
nastanka kroničnih zapletov sladkorne bolezni. Z napredkom kirurgije in novimi imunosupresivnimi zdravili je v zadnjih desetletjih prišlo do bistvenega izboljšanja preživetja bolnikov in presadkov ter povečane kakovosti življenja po presaditvi. Presaditev trebušne slinavke je danes metoda izbire, s katero nadomestimo endokrino funkcijo trebušne slinavke, vzpostavimo normoglikemijo in preprečimo nastanek sekundarnih zapletov sladkorne bolezni. Med presaditve trebušne slinavke prištevamo sočasno presaditev trebušne slinavke in ledvice, presaditev
samo trebušne slinavke, presaditev dela trebušne slinavke ter presaditev otočkovtrebušne slinavke. Enoletno preživetje bolnikov po presaditvi trebušne slinavke znaša 96 %, petletno pa 80 %. Preživetje je najbolj optimalno pri sočasni presaditvi trebušne slinavke in ledvice.Pancreas transplantation (PT) is a vital therapeutic option for patients with diabetes mellitus (DM)|, particularly those with end-stage renal disease (ESRD) or severe metabolic complications. Over the past several decades, advancements in surgical techniques, organ preservation and procurement methods, and immunosuppression therapies have significantly enhanced post-transplant patient survival, graft survival, and quality of life. The primary goals of
PT are to achieve effective and stable glycemic control, often leading to insulin independence, improve the
patient’s quality of life, and reduce secondary complications associated with DM. PT encompasses a variety
of procedures, including PT alone from a living donor, whole PT, pancreas with kidney transplantation,
and pancreatic islet cell transplantation. PT is most commonly performed in conjunction with kidney transplantation for selected patients with DM and ESRD. Over the past decade, unadjusted patient survival rates have exceeded 96% at 1-year post-transplant and >80% at 5 years
